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Abstract
Pulmonary toxoplasmosis is rare, particularly in the era of
highly active antiretroviral therapy (HAART). Here, we
describe two severe cases in patients not known to be HIV-
infected. In both patients, early diagnosis and therapy led to a
favourable outcome. Pulmonary toxoplasmosis should be
considered in the differential diagnosis in potentially HIV-
infected patients with respiratory symptoms.
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Introduction
Highly active antiretroviral therapy (HAART) and anti-
biotic prophylaxis against opportunistic infections have
resulted in a dramatic decrease of morbidity and mortality
[1–3]. However, patients infected with HIV – also in
developed countries – may still present with severe
opportunistic infections. Most of these events are among
those newly diagnosed with HIV at a late stage of disease
[4–6].
Toxoplasmosis is the most common parasitic oppor-
tunistic infection of the central nervous system in AIDS
patients, who are not on appropriate prophylaxis [7].
Extracerebral sites may be involved with or without
toxoplasmic encephalitis [8–11]. HIV-related pulmonary
toxoplasmosis was first described in 1984. It was respon-
sible for less than 1% of the pulmonary complications of
HIV infection [12]. In a French national survey, the
prevalence of extracerebral toxoplasmosis among HIV-
infected patients in the pre-HAART era was 1.5–2%. Of
199 patients with extracerebral toxoplasmosis, the lungs
were involved in 26% and were the second most common
extracerebral site after involvement of the eyes [9]. Here,
we present two cases with pulmonary toxoplasmosis.
Case 1
A 26-year-old Brazilian heterosexual patient presented to the
emergency department because of a three-day history of malaise,
rapid progressive dyspnoea, chest pain and fever, but no cough.
In addition, he complained about diarrhoea and weight loss of
4 kg during the past four months. His medical history was
unremarkable. He was not known to be HIV-positive. On
examination, the patient was alert and oriented, but in respira-
tory distress. His temperature was 37.8 C, blood pressure 110/
45 mmHg, pulse 127 min–1; the respirations were 50–60 breaths
per minute, with an oxygen saturation of 50% without supple-
mental oxygen. Chest examination did not reveal rhonchi or
crackles. The axillary and inguinal lymph nodes were enlarged;
the remainder of the examination was normal. A chest radio-
graph showed extensive diffuse bilateral alveolar infiltrates
(Figure 1a). An electrocardiogram was unremarkable. Labora-
tory test results included a mild normocytic anaemia with a
haemoglobin level of 11.1 g/dl, a lymphocytopaenia with
410 cells/ll, C-reactive protein (CRP) of 175 mg/l (<5), an ele-
vated lactate dehydrogenase (LDH) of 2,640 U/l (240–420) and
an aspartate aminotransferase (AST) of 130 U/l (10–50). A
blood gas analysis with room air revealed a partial pressure of O2
(pO2) of 5.1 kPa, a partial pressure of CO2 (pCO2) of 3.5 kPa
and a pH of 7.47. An HIV test turned out to be positive. The
patient was transferred to the intensive care unit. Besides cef-
triaxone and clarithromycin, high-dose trimethoprim-sulpha-
methoxazole and prednisone were started. During the next day,
his condition worsened, with increasing dyspnoea and respiratory
exhaustion and mechanical ventilation was required. His CD4
cell count was 21 cells/ll and an HIV-1 viral load was
348,000 copies/ml. A bronchoalveolar lavage (BAL) was per-
formed. In Giemsa and indirect immunofluorescence stains,
toxoplasma tachyzoites were identified (Figure 1b, c). There was
no evidence of Pneumocystis jirovecii and acid-fast bacilli.
Toxoplasma serology turned out to be highly positive with
IgG > 549 IU/l and negative IgM antibodies. Pulmonary toxo-
plasmosis with acute respiratory distress syndrome (ARDS) in a
patient with advanced HIV infection was diagnosed. Therapy was
changed to sulphadiazine and pyrimethamine plus folinic acid.
After three days, the patient was extubated and he subsequently
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recovered rapidly. He was discharged from the hospital four
days later.
Case 2
A 38-year-old immigrant from Nigeria was admitted with low-
grade temperature, productive cough lasting for 14 days, pro-
gressive headache for a few days and aggressive behaviour on the
day of admission. His medical history was unremarkable.
On admission, his body temperature was 36.7 C, blood
pressure 110/77 mmHg, heart rate 60 min–1, frequency of respi-
ration 14 min–1 and pulmonary examination revealed generalised
wheezing. The patient was confused and somnolent, with a
fluctuating Glasgow Coma Scale (GCS) score between 5 and 13.
He had ataxia and dysarthria, but no meningeal symptoms.
Significant laboratory values were as follows: microcytic anaemia
with a haemoglobin level of 10.3 g/dl, lymphopaenia with
440 cells/ll, CRP 15 mg/l (<5), LDH 636 U/l (150–420), AST
85 U/l (<50) and alanine aminotransferase (ALT) 80 U/l (<50).
HIV serology turned out to be positive. The CD4 cell count was
5 cells/ll and HIV1-RNA 1,620,000 copies/ml. Assays for toxo-
plasma antibodies were positive for IgG (not quantified) and
negative for IgM. An electrocardiogram was normal. Chest
X-ray revealed bilateral, diffuse patchy infiltrates and increased
interstitial striation. Chest computed tomography (CT) scan also
showed bilateral, patchy infiltrates (Figure 1d) and in a cranial
CT scan, edema and midline shift was found. One day later,
cranial magnetic resonance imaging (MRI) revealed multiple
abscesses. Central nervous system (CNS) lymphoma was ruled
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Figure 1. Chest radiograph and
bronchoalveolar fluid of case 1:
diffuse bilateral alveolar
infiltrates (a), Giemsa staining
(b) and indirect
immunofluorescence staining
(c) with toxoplasma tachyzoites
(black arrow). Chest computed
tomography (CT) scan and
bronchoalveolar fluid of case 2:
extensive bilateral, patchy
infiltrates (d), Giemsa staining
(e) revealing toxoplasma
tachyzoites (black arrow) and
Pneumocystis jirovecii (red
arrow) and toluidine blue O
staining with P. jirovecii (f).
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out by positron emission tomography (PET) scan. A BAL was
performed: the Giemsa-stained specimen revealed tachyzoites of
Toxoplasma gondii, together with cysts of P. jirovecii (Figure 1e)
that were confirmed by toluidine blue O staining (Figure 1f) and
immunofluorescence staining (not shown). Pulmonary and
cerebral toxoplasmosis with contemporaneous pulmonary
pneumocystis infection was diagnosed. Treatment with sulph-
adiazine, pyrimethamine, folinic acid and atovaquone was
started. The former drug was prescribed instead of trimethoprim-
sulphamethoxazole to minimise sulphonamide toxicity. In the
following several days, the patient’s condition progressively im-
proved. After 17 days, he was discharged from the hospital.
Discussion
Here, we present two cases of pulmonary toxoplasmosis.
This is a very rare manifestation of a common opportu-
nistic infection in AIDS patients. Strikingly in both pa-
tients, the HIV status was unknown when they presented
to the emergency room.
The first case illustrates that pulmonary toxoplasmo-
sis can rapidly progress to a life-threatening state. Toxo-
plasma pneumonitis is also known to cause severe
systemic infections with ARDS [13].
The second patient presented with toxoplasmosis
manifesting in two locations and, in addition, contempo-
raneously suffered from a second opportunistic infection,
a P. jirovecii pneumonia. Toxoplasmosis involving several
locations have been described [8, 10, 11]. In a French case
series, 11 of 64 patients (17%) presented with toxoplas-
mosis including the lungs and the brain [14]. In addition,
there are rare published reports of patients with concur-
rent pulmonary toxoplasmosis and pneumocystis infection
[8, 14]. However, these reports originated from the pre-
HAART era, when, in general, the incidence of oppor-
tunistic infections was higher by magnitudes in developed
countries when compared to today [15].
Usually, T. gondii pneumonia manifests with fever,
dyspnoea and non-productive cough. The most common
finding on chest radiographs is bilateral diffuse interstitial
infiltrates [8, 14, 16]. The clinical and radiological
appearance may be indistinguishable from the far more
common P. jirovecii pneumonia. As compared with
pneumocystis pneumonia, the clinical onset and the evo-
lution of symptoms are more rapid in toxoplasma pneu-
monia [8]. A blood level of LDH > 600 U/l is more likely
to be associated with toxoplasmosis than pneumocystis
pneumonia [17]. A toxoplasma antibody titre of >150 U/
ml is an important predictor of cerebral and extracerebral
toxoplasmosis [18]. Finally, pulmonary toxoplasmosis oc-
curs mainly in patients with severe immunodeficiency,
with a CD4 cell count of 40 ± 75 cells/ll [14].
Mortality in immunosuppressed patients with pul-
monary toxoplasmosis is high: in the French survey, 37%
of HIV-infected patients with toxoplasma pneumonia
died [14] and in a meta-analysis, mortality among
immunosuppressed persons with pulmonary toxoplas-
mosis was 40% [16]. As toxoplasma pneumonitis is
clinically difficult do diagnose and is associated with a
considerable mortality, it is necessary to force the diag-
nosis by the microbiological examination of respiratory
samples. Especially in patients with severe clinical pic-
tures or not responding to therapy, it is judicious to
perform a BAL with cytological examination of BAL
fluid, using appropriate special stains to detect toxo-
plasma organisms. In both of our cases, early diagnosis
led to a favourable outcome.
In resource-poor countries, for example, in Africa
with a toxoplasmosis seroprevalence of up to 78% [19]
and more HIV-infected patients with very low CD4 cell
counts, the prevalence of pulmonary toxoplasmosis might
be higher than in industrialised countries. However, in
these countries, diagnostic possibilities are often very
limited and in the absence of respiratory samples, clini-
cians need to consider an empiric toxoplasmal therapy,
particularly in the presence of risk factors (see above) and
non-responsiveness to therapy.
In summary, pulmonary toxoplasmosis is an infre-
quent but severe opportunistic infection in HIV-positive
patients that still occurs in the era of HAART. The two
cases emphasise the importance of considering toxoplas-
mosis early in the differential diagnosis in (potentially)
HIV-infected patients presenting with respiratory symp-
toms and bilateral pulmonary infiltrates. Early diagnosis
and initiation of specific therapy is essential.
Conflict of interest statement. None declared by all
authors.
References
1. Antiretroviral Therapy Cohort Collaboration: Life expectancy of
individuals on combination antiretroviral therapy in high-
income countries: a collaborative analysis of 14 cohort studies.
Lancet 2008; 372: 293–299.
2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M,
Rickenbach M, Malinverni R, Vernazza P, Battegay M: Impact
of new antiretroviral combination therapies in HIV infected
patients in Switzerland: prospective multicentre study. Swiss
HIV Cohort Study. BMJ 1997; 315: 1194–1199.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J,
Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and
mortality among patients with advanced human immunodefi-
ciency virus infection. HIV Outpatient Study Investigators. N
Engl J Med 1998; 338: 853–860.
4. Sabin CA, Smith CJ, Gumley H, Murphy G, Lampe FC, Phillips AN,
Prinz B, Youle M, Johnson MA: Late presenters in the era of
highly active antiretroviral therapy: uptake of and responses to
antiretroviral therapy. AIDS 2004; 18: 2145–2151.
5. Battegay M, Fluckiger U, Hirschel B, Furrer H: Late presentation
of HIV-infected individuals. Antivir Ther 2007; 12: 841–851.
6. Girardi E, Sabin CA, Monforte AD: Late diagnosis of HIV infec-
tion: epidemiological features, consequences and strategies to
encourage earlier testing. J Acquir Immune Defic Syndr 2007; 46
Suppl 1: S3–S8.
Infection 38 Æ 2010 Æ No. 2 143
H. Kovari et al. Pulmonary Toxoplasmosis and HIV
7. Porter SB, Sande MA: Toxoplasmosis of the central nervous
system in the acquired immunodeficiency syndrome. N Engl J
Med 1992; 327: 1643–1648.
8. Oksenhendler E, Cadranel J, Sarfati C, Katlama C, Datry A,
Marche C, Wolf M, Roux P, Derouin F, Clauvel JP: Toxoplasma
gondii pneumonia in patients with the acquired immunodefi-
ciency syndrome. Am J Med 1990; 88: 18N–21N.
9. Rabaud C, May T, Amiel C, Katlama C, Leport C, Ambroise-
Thomas P, Canton P: Extracerebral toxoplasmosis in patients
infected with HIV. A French National Survey. Medicine
(Baltimore) 1994; 73: 306–314.
10. Eza DE, Lucas SB: Fulminant toxoplasmosis causing fatal
pneumonitis and myocarditis. HIV Med 2006; 7: 415–420.
11. Signorini L, Gulletta M, Coppini D, Donzelli C, Stellini R, Manca
N, Carosi G, Matteelli A: Fatal disseminated toxoplasmosis
during primary HIV infection. Curr HIV Res 2007; 5: 273–274.
12. Murray JF, Felton CP, Garay SM, Gottlieb MS, Hopewell PC,
Stover DE, Teirstein AS: Pulmonary complications of the
acquired immunodeficiency syndrome. Report of a National
Heart, Lung, and Blood Institute workshop. N Engl J Med 1984;
310: 1682–1688.
13. Gandhi S, Lyubsky S, Jimenez-Lucho V: Adult respiratory distress
syndrome associated with disseminated toxoplasmosis. Clin
Infect Dis 1994; 19: 169–171.
14. Rabaud C, May T, Lucet JC, Leport C, Ambroise-Thomas P,
Canton P: Pulmonary toxoplasmosis in patients infected with
human immunodeficiency virus: a French National Survey. Clin
Infect Dis 1996; 23: 1249–1254.
15. Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P,
Rickenbach M, Robins JM, Egger M, Swiss HIV Cohort Study:
Long-term effectiveness of potent antiretroviral therapy in
preventing AIDS and death: a prospective cohort study. Lancet
2005; 366: 378–384.
16. Pomeroy C, Filice GA: Pulmonary toxoplasmosis: a review. Clin
Infect Dis 1992; 14: 863–870.
17. Pugin J, Vanhems P, Hirschel B, Chave JP, Flepp M: Extreme
elevations of serum lactic dehydrogenase differentiating pul-
monary toxoplasmosis from pneumocystis pneumonia. N Engl J
Med 1992; 326: 1226.
18. Belanger F, Derouin F, Grangeot-Keros L, Meyer L: Incidence and
risk factors of toxoplasmosis in a cohort of human immuno-
deficiency virus-infected patients: 1988–1995. HEMOCO and
SEROCO Study Groups. Clin Infect Dis 1999; 28: 575–581.
19. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G,
N’Gbichi JM, Yeboue K, Hondé M, Diomande M, Giordano C,
Doorly R, Brattegaard K, Kestens L, Smithwick R, Kadio A, Ezani
N, Yapi A, De Cock KM: The mortality and pathology of HIV
infection in a west African city. AIDS 1993; 7: 1569–1579.
144 Infection 38 Æ 2010 Æ No. 2
H. Kovari et al. Pulmonary Toxoplasmosis and HIV
